Manage Tickers

Has my stock been accused of fraud?Join over 160k users who know.

Ticker Price Change($) Change(%) Shares Volume Prev Close Open Gain($) Gain(%)
Ticker Status Jurisdiction Filing Date CP Start CP End CP Loss Deadline
Ticker Case Name Status CP Start CP End Deadline Settlement Amt
Ticker Name Date Analyst Firm Up/Down Target ($) Rating Change Rating Current
Analyst Rating Guide

News

Back

Valneva's 2023 Revenues €153.7M, Down From €361.3M YoY; Product Sales Grew 26% YoY To €144.6M

Author: Benzinga Newsdesk | February 15, 2024 02:33am

Total revenues of €153.7 million, including product sales of €144.6 million

  • Product sales surpassed pre-pandemic (2019) sales by 12% and 2022 sales by 26%
  • Excluding COVID-19 vaccine sales, product sales grew by 63% compared to 2022  

Cash position of €126.1 million at December 31, 2023

  • Excludes recent sale of the Priority Review Voucher (PRV) for $103 million (€95 million)                                                                              
  • Reflects significant payments related to the Phase 3 Lyme disease study, for which Valneva’s cost contributions are expected to be completed in the first half 2024

Posted In: VALN


CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION

CORE Finalist